[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100606813":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":20,"responsibleParty":21,"collaborators":23,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":30,"acronym":20,"eligibilityCriteria":31,"healthyVolunteers":28,"sex":32,"minAge":33,"maxAge":34,"enrollmentInfo":35,"targetDuration":20,"studyType":38,"phases":39,"briefSummary":41,"conditions":42,"keywords":20,"overallStatus":44,"whyStopped":20,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":20},{"fullName":5,"class":6},"St. Olavs Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"FAPI-PET\u002FMRI","EXPERIMENTAL","The patients will be injected 2 MBq\u002Fkg 18F-FAPI, prior to PET\u002FMRI acquisition",[13],"Diagnostic Test: FAPI PET\u002FMR",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","FAPI PET\u002FMR","The patients will be injected intravenously with 2 MBq\u002Fkg 18F-FAPI, 60 minutes before the PET\u002FMRI acquisition. The PET\u002FMRI examinations will be performed on a Siemens Biograph mMR (Siemens Healthcare, Erlangen, Germany) with software version VE11P. Static PET will be acquired simultaneously with MRI using two protocols; a one bed position protocol in prone position covering the breast and a whole body 4-5 bed position protocol in supine position covering brain to thighs. Total acquisition time of the breast protocol will be approximately 20 minutes. Total acquisition time of the whole-body protocol will be approximately 30 minutes.",[9],null,{"type":22,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[24],{"name":25,"class":6},"Norwegian University of Science and Technology","100606813","piloting-18f-fapi-petmri-for-applications-in-breast-cancer-100606813",false,"NCT07180433","Piloting 18F-FAPI PET\u002FMRI for Applications in Breast Cancer","Inclusion Criteria:\n\n* Inclusion criteria are accepting to undergo 18F-FAPI PET\u002FMRI examinations and\n\n  1. diagnosed with local invasive breast cancer,\n  2. scheduled for neoadjuvant therapy as primary treatment,\n  3. has recurrent or new breast cancer, or\n  4. scheduled for neoadjuvant therapy as primary treatment with FDG-PET\u002FCT applied for staging.\n\nExclusion Criteria:\n\n* other primary malignancies than breast cancer, renal insufficiency or know allergy towards contrast agents, and MR incompatible implants.","FEMALE","18 Years","80 Years",{"count":36,"type":37},60,"ESTIMATED","INTERVENTIONAL",[40],"NA","Breast cancer is the most common type of cancer in Norwegian women, with 4,224 new cases in 2022. More precise diagnosis are expected to result in more accurate assessment of treatment effect, and to contribute to both providing better treatment and reducing overtreatment. Fibroblast activating protein (FAP) is expressed in the tumor stroma of 90% of all epithelial-based tumors, including breast tumors. Inhibitors for this protein (FAPI) has been developed for use as radioactive tracers. Breast tumors of various histopathological types, and local metastatic lymph nodes, have shown high uptake for such tracers. The main aim of this project is to establish 18F-FAPI PET\u002FMRI for use in breast cancer in a wide range of disease stages. We will evaluate how FAPI PET\u002FMRI correlates with histopathological assessment, the method's ability to grade tumors - including assessment of treatment - compared to CT, scintigraphy and FDG PET\u002FCT, and ability to detect local recurrence.",[43],"Breast Neoplasm Female","NOT_YET_RECRUITING","2025-09-11",{"date":47,"type":48},"2025-09-18","ACTUAL",{"date":50,"type":37},"2025-10-01",{"date":52,"type":37},"2038-12-31",{"name":5,"class":6}]